Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05866809
Other study ID # HK-660S-201
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date October 28, 2021
Est. completion date July 24, 2023

Study information

Verified date May 2023
Source CuromeBiosciences
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this study is to evaluate the improvement of bile duct strictures following the administration of HK-660S in patients with Primary Sclerosing Cholangitis(PSC). Percentage of subjects who show improvement of severity of PSC as assessed by Magnetic Resonance Cholangiopancreatography(MRCP) at Week 12 from baseline, with improvement defined as a decrease of -1 or more in the MRCP and change of alkaline phosphatase(ALP) level will be assessed at Week 12 from baseline.


Description:

Sclerosing cholangitis is a rare, chronic, cholestatic liver disease caused by inflammation and fibrosis of the intrahepatic/extrahepatic biliary tract. Its pathophysiology involves destruction and stricture of the bile duct due to diffuse inflammation and fibrosis of the bile duct. The selected subjects will be randomly assigned to either active or placebo groups and administered 100 mg of HK-660S or placebo (1 tablet) twice a day for 12 weeks. After Visit 2, subjects will visit the study center at Week 4 (Visit 3), Week 8 (Visit 4), Week 12 (Visit 5 / End of Treatment), and Week 16 (Visit 6 / Follow-up) to assess efficacy and safety.


Recruitment information / eligibility

Status Completed
Enrollment 23
Est. completion date July 24, 2023
Est. primary completion date June 23, 2023
Accepts healthy volunteers No
Gender All
Age group 17 Years and older
Eligibility Inclusion Criteria: - Male or female subjects aged = 17 years - Subjects who have a diagnosis of PSC - Subjects who are able to understand the information provided directly or via his/her representative and give voluntary, written consent to participate in the study. Exclusion Criteria: - Subjects with an average alcohol intake of more than 20g per day within 2 years prior to screening. - Subjects who have a diagnosis of type 1 diabetes or uncontrolled type 2 diabetes (HbA1c = 9%) prior to screening. - Subjects who have chronic liver diseases other than PSC - Subjects who have a diagnosis of primary biliary cirrhosis or secondary sclerosing cholangitis in MRCP or Endoscopic Retrograde Cholangiopancreatography(ERCP) prior to screening. - Subjects who have obstacles to MRCP implementation - Subjects who have a positive result of hepatitis B surface antigen (HBsAg test) and/or hepatitis C antibody (HCV-Ab test) - Subjects who have Alanine Aminotransferase(ALT) or Aspartate aminotransferase(AST) > 10 x upper limit of normal(ULN) - Subjects who have serum creatinine = 2 mg/dl - Subjects who have weight changes of 5 kg or more within 6 months prior to screening - Subjects who are deemed unsuitable for participation in the study at Screening, at the discretion of the investigator, due to the following: cirrhosis, severe metabolic disease, severe renal failure, severe lung disease, severe neuro/psychiatric disease, muscle disease, etc. - Subjects who have any clinically significant cardiovascular diseases - Subjects who have thyroid diseases including hyperthyroidism and hypothyroidism - Subjects who have a history of immune diseases - Subjects who had bariatric surgery within 6 months prior to screening - Subjects who had liver transplant surgery - Subjects who have a diagnosis of HIV infection - Subjects who have a history of chronic infections or have severe or life-threatening infections, or symptoms that may be considered related to infections - Subjects diagnosed with a malignant tumor without complete cure within 5 years prior to screening - Subjects whose medication history includes any of the following drugs, within a period of 5 times the half-life of the respective drug prior to screening: - Therapeutics agents for steatohepatitis: thiazolidinediones, high-dose vitamin E (800 IU/day), pentoxifylline - Medications possibly related to PSC: high-dose ursodeoxycholic acid (UDCA; doses smaller than 23 mg/kg/day may be permitted if administered stably without change in dosage from 3 months prior to screening), immunosuppressants, obeticholic acid (OCA), azathioprine, budesonide, docosahexaenoic acid, methotrexate, metronidazole, minocycline, mycophenolate mofetil, nicotine, pentoxifylline, pirfenidone, prednisolone, systemic glucocorticoids, tacrolimus, vancomycin - Subjects who administered herbal medicine or folk remedies to improve fatty liver disease within 2 weeks prior to screening - Subjects who have a history of alcohol or drug abuse within 5 years prior to screening - Subjects who have a hypersensitivity to any excipients of the study drug - Subjects who participated in another drug trial within 30 days prior to screening - Subjects who are considered inappropriate to participate in clinical trials at the discretion of the investigator

Study Design


Intervention

Drug:
HK-660S
Administered orally
Placebo
Administered orally

Locations

Country Name City State
Korea, Republic of ASAN Medical Center Seoul
Korea, Republic of Samsung Medical Center Seoul
Korea, Republic of Seoul National University Hospital Seoul
Korea, Republic of Severance Hospital Seoul

Sponsors (1)

Lead Sponsor Collaborator
CuromeBiosciences

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary MRCP Percentage of subjects who show improvement of severity of PSC as assessed by MRCP with improvement defined as a decrease of -1 or more in the MRCP score Week 12 from baseline
Primary ALP Change of ALP level Week 12 from baseline
See also
  Status Clinical Trial Phase
Completed NCT02239211 - A Trial of BTT1023 in Patients With Primary Sclerosing Cholangitis Phase 2
Withdrawn NCT03216876 - A Study Of Ursolic Acid For Primary Sclerosing Cholangitis Phase 1
Recruiting NCT02605213 - Effect and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis Patients Phase 4
Recruiting NCT01688024 - Mitomycin C Therapy for Patients With Primary Sclerosing Cholangitis Phase 2
Completed NCT03041662 - Surveillance Study for Early Detection of Cholangiocarcinoma (CCA) in Primary Sclerosing Cholangitis (PSC)
Recruiting NCT05618145 - National Database on Primary Sclerosing Cholangitis (PSC)
Active, not recruiting NCT02446665 - Disease Status in Primary Sclerosing Cholangitis by Elastography N/A
Completed NCT02247934 - Development of a Patient-Reported Outcome Measure to Assess Symptoms in Patients With Primary Sclerosing Cholangitis (PSC) N/A
Terminated NCT01142323 - Pilot Study of Fenofibrate for PSC Phase 1/Phase 2
Completed NCT01088607 - Safety and Efficacy Study of Ursodeoxycholic Acid Therapy in Pediatric Primary Sclerosing Cholangitis Phase 1
Terminated NCT04060147 - Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis Phase 1
Recruiting NCT04133792 - Effect of Simvastatin on the Prognosis of Primary Primary Sclerosing Cholangitis (PSC) Phase 3
Active, not recruiting NCT04595825 - CM-101 in PSC Patients -The SPRING Study Phase 2
Recruiting NCT03183570 - Detection of Integrin avb6 in IPF, PSC, and COVID19 Using PET/CT Early Phase 1
Completed NCT02943460 - Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Sclerosing Cholangitis Without Cirrhosis Phase 2
Completed NCT00951327 - Cholangioscopy Using Narrow Band Imaging (NBI) in Patients With Primary Sclerosing Cholangitis (PSC) Undergoing Endoscopic Retrograde Cholangiopancreatogram (ERCP) N/A
Completed NCT04024813 - A Study to Evaluate the Safety, and Tolerability, and Efficacy of Seladelpar in Patients With PSC Phase 2
Recruiting NCT05912387 - Statin Therapy in Primary Sclerosing Cholangitis (PSC): a Multi-omics Study Early Phase 1
Completed NCT02884557 - NKT Role in the Regulation of the Inflammatory Bowel Disease N/A
Recruiting NCT01398917 - Short-term Stenting Versus Balloon Dilatation for Dominant Strictures in Primary Sclerosing Cholangitis Phase 3